Cargando…

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia

BACKGROUND: Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point mutations which we found to disrupt highly conserved biophysical interactions in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walker, Janek S., Hing, Zachary A., Harrington, Bonnie, Baumhardt, Jordan, Ozer, Hatice Gulcin, Lehman, Amy, Giacopelli, Brian, Beaver, Larry, Williams, Katie, Skinner, Jordan N., Cempre, Casey B., Sun, Qingxiang, Shacham, Sharon, Stromberg, Benjamin R., Summers, Matthew K., Abruzzo, Lynne V., Rassenti, Laura, Kipps, Thomas J., Parikh, Sameer, Kay, Neil E., Rogers, Kerry A., Woyach, Jennifer A., Coppola, Vincenzo, Chook, Yuh Min, Oakes, Christopher, Byrd, John C., Lapalombella, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809770/ https://www.ncbi.nlm.nih.gov/pubmed/33451349 http://dx.doi.org/10.1186/s13045-021-01032-2

Ejemplares similares

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation
por: Baumhardt, Jordan M., et al.
Publicado: (2020)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
por: Hing, Zachary A., et al.
Publicado: (2023)

Structural prerequisites for CRM1-dependent nuclear export signaling peptides: accessibility, adapting conformation, and the stability at the binding site
por: Lee, Yoonji, et al.
Publicado: (2019)

Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation
por: Mitchell, Shaneice, et al.
Publicado: (2021)

Correlation of CRM1-NES affinity with nuclear export activity
por: Fu, Szu-Chin, et al.
Publicado: (2018)

Heterozygous mutation of cysteine(528) in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
por: Neggers, Jasper Edgar, et al.
Publicado: (2016)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia
por: Lai, Tzung-Huei, et al.
Publicado: (2022)

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
por: Taylor‐Kashton, Cheryl, et al.
Publicado: (2016)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions
por: Zhang, Pu, et al.
Publicado: (2022)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Lack of Allelic Exclusion in B Cell Chronic Lymphocytic Leukemia
por: Rassenti, Laura Z., et al.
Publicado: (1997)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
por: Turner, Joel G., et al.
Publicado: (2016)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
por: Aboukameel, Amro, et al.
Publicado: (2018)

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
por: Yoshimura, Mariko, et al.
Publicado: (2014)

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
por: Yang, Jennifer, et al.
Publicado: (2014)

P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA
por: Frigault, M., et al.
Publicado: (2022)

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

XPO1-dependent nuclear export as a target for cancer therapy
por: Azizian, Nancy G., et al.
Publicado: (2020)

Regulation of XPO5 phosphorylation by PP2A in hepatocellular carcinoma
por: Li, Jiao, et al.
Publicado: (2022)

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
por: Zhang, Weiguo, et al.
Publicado: (2018)

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
por: Sher, Steven, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fn66b3aqegbs7fak7oerr8fmif